arrow
M

Ming-Huang Chen

台北榮民總醫院
H指数:37
被引数:5,374

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Global prevalence of FGFR2b protein overexpression in advanced gastric cancer and gastroesophageal junction cancers: pooled analysis of two bemarituzumab phase III studies

FGFR2b蛋白过表达在晚期胃癌和胃食管结合部癌症中的全球流行率:两项bemarituzumab III期研究的合并分析

2026-05-260
OAAI
A phase I/II study using cabozantinib and lanreotide as treatments for advanced GEP-NETs for which molecular targeted therapy or chemotherapy have failed (SCALET): TCOG T2221 study

I/II期研究使用卡博替尼和兰瑞肽治疗分子靶向治疗或化疗失败的晚期GEP-NETs(SCALET):TCOG T2221研究

2026-01-010
OAAI
FGFR2 Fusions or Rearrangements in Young Intrahepatic and Perihilar Cholangiocarcinoma Patients: Key Genetic Insights From a Pan-Asian Study

FGFR2融合或重排在年轻肝内及肝门部胆管癌患者中的关键遗传学见解:一项泛亚洲研究

2025-09-160
OAAI
Clinical outcomes of gastroenteropancreatic neuroendocrine neoplasms in Taiwan: A multicenter registry study—TCOG T1214 study

台湾地区胃肠胰神经内分泌新生物的临床结局:一项多中心登记研究—TCOG T1214研究

Cancer
IF5.1
2025-08-200
OAAI
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer (vol 9, 103647, 2024)
2025-01-010
OAAI
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer

泛亚适应ESMO临床实践指南,用于胆道癌患者的诊断,治疗和随访

2024-08-010
OAAI
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1) : updated overall survival from a randomised phase 3 study
2024-08-0115
PRE
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer

泛亚适应的ESMO临床实践指南,用于胃癌患者的诊断,治疗和随访

2024-02-0115
OAAI